16-89145311-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 6P and 1B. PM1PM2PP3PP5BP4
The NM_001243279.3(ACSF3):c.1411C>T(p.Arg471Trp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00017 in 1,614,020 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00017 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00017 ( 0 hom. )
Consequence
ACSF3
NM_001243279.3 missense
NM_001243279.3 missense
Scores
14
3
2
Clinical Significance
Conservation
PhyloP100: 7.22
Genes affected
ACSF3 (HGNC:27288): (acyl-CoA synthetase family member 3) This gene encodes a member of the acyl-CoA synthetase family of enzymes that activate fatty acids by catalyzing the formation of a thioester linkage between fatty acids and coenzyme A. The encoded protein is localized to mitochondria, has high specificity for malonate and methylmalonate and possesses malonyl-CoA synthetase activity. Mutations in this gene are a cause of combined malonic and methylmalonic aciduria. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Sep 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 5 ACMG points.
PM1
In a binding_site (size 0) in uniprot entity ACSF3_HUMAN
PM2
Very rare variant in population databases, with high coverage;
PP3
Multiple lines of computational evidence support a deleterious effect 10: AlphaMissense, BayesDel_addAF, BayesDel_noAF, Cadd, Dann, Eigen, M_CAP, MutationAssessor, PROVEAN, REVEL [when max_spliceai, FATHMM_MKL, MetaRNN, MutationTaster was below the threshold]
PP5
Variant 16-89145311-C-T is Pathogenic according to our data. Variant chr16-89145311-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 31137.We mark this variant Likely_pathogenic, oryginal submissions are: {Pathogenic=1, Uncertain_significance=3, Likely_pathogenic=4}.
BP4
Computational evidence support a benign effect (MetaRNN=0.37387383). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 152140Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
26
AN:
152140
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000318 AC: 80AN: 251262Hom.: 0 AF XY: 0.000324 AC XY: 44AN XY: 135856
GnomAD3 exomes
AF:
AC:
80
AN:
251262
Hom.:
AF XY:
AC XY:
44
AN XY:
135856
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000170 AC: 248AN: 1461880Hom.: 0 Cov.: 32 AF XY: 0.000186 AC XY: 135AN XY: 727240
GnomAD4 exome
AF:
AC:
248
AN:
1461880
Hom.:
Cov.:
32
AF XY:
AC XY:
135
AN XY:
727240
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000171 AC: 26AN: 152140Hom.: 0 Cov.: 33 AF XY: 0.000188 AC XY: 14AN XY: 74314
GnomAD4 genome
AF:
AC:
26
AN:
152140
Hom.:
Cov.:
33
AF XY:
AC XY:
14
AN XY:
74314
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
25
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:6Uncertain:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Combined malonic and methylmalonic acidemia Pathogenic:3Uncertain:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 14, 2011 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 26, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 24, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Feb 15, 2019 | The ACSF3 c.1411C>T; p.Arg471Trp variant (rs138680796), is reported in the literature in the homozygous state in two individuals affected with combined malonic and methylmalonic aciduria (CMAMMA) (Alfares 2011, Sloan 2011). This variant is found in the Ashkenazi Jewish population with an overall allele frequency of 0.71% (73/10360 alleles) in the Genome Aggregation Database, though at least one affected individual with this variant was of Ashkenazi descent (Alfares 2011). The arginine at codon 471 is moderately conserved and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Another variant at the same codon (p.Arg471Gln) was also reported in an individual with CMAMMA, though its clinical significance remains uncertain (Sloan 2011). Given the lack of clinical and functional data, the significance of the p.Arg471Trp variant is uncertain at this time. References: Alfares A et al. Combined malonic and methylmalonic aciduria: exome sequencing reveals mutations in the ACSF3 gene in patients with a non-classic phenotype. J Med Genet. 2011 Sep;48(9):602-5. Sloan JL et al. Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria. Nat Genet. 2011 Aug 14;43(9):883-6. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 22, 2021 | Variant summary: ACSF3 c.1411C>T (p.Arg471Trp) results in a non-conservative amino acid change located in the AMP-dependent synthetase/ligase domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00032 in 251262 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in ACSF3 causing Combined Malonic And Methylmalonic Aciduria (0.00032 vs 0.0058), allowing no conclusion about variant significance. c.1411C>T has been reported in the literature in two individuals in the homozygous state affected with Combined Malonic And Methylmalonic Aciduria, however with benign clinical courses (ie. elevated MA and MMA levels in urine and plasma, without other major clinical features; Alfares_2011, Sloan_2012). In a functional study, fibroblast cell lines from a patient homozygous for the variant displayed elevated MA and MMA in culture media, therefore recapitulating the biochemical outcome observed in the two reported patients (Wehbe_2019). Additionally, the equivalent residue in E. coli was shown to result in the complete loss of fatty acyl-CoA synthetase enzymatic activity (Black_1997). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Four labs classified the variant as VUS while one classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 20, 2018 | This sequence change replaces arginine with tryptophan at codon 471 of the ACSF3 protein (p.Arg471Trp). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs138680796, ExAC 0.04%). This variant has been observed in individuals affected with combined malonic and methylmalonic aciduria (PMID: 29858964, 21841779, 21785126). ClinVar contains an entry for this variant (Variation ID: 31137). Experimental studies have shown that this missense change disrupts ACSF3 protein function in vitro (PMID: 9030548). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Mar 08, 2019 | DNA sequence analysis of the ACSF3 gene demonstrated a sequence change, c.1411C>T, in exon 9 that results in an amino acid change, p.Arg471Trp. The p.Arg471Trp change affects a moderately conserved amino acid residue located in a domain of the ACSF3 protein that is known to be functional. The p.Arg471Trp substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, CADD, REVEL). This sequence change has been described in the gnomAD database with a low global population frequency of 0.03%, but a relatively high frequency of 0.7% in the Ashkenazi Jewish population (dbSNP rs138680796). The p.Arg471Trp change has been identified in the homozygous state in an Ashkenazi Jewish patient with combined malonic and methylmalonic aciduria but who was clinically asymptomatic at 14 years of age (PMID: 21785126). The patient was initially identified by newborn screening (PMID: 10356133). PMID: 21841779 reported a 66 year old woman who is apparently homozygous for the p.Arg471Trp change who exhibited elevated malonic and methylmalonic acid in plasma and urine. This individual reported incontinence and mild memory issues. Additionally, a different sequence changes affecting the same amino acid residue (p.Arg471Gln) has been described in the compound heterozygous state with a second missense variant a patient with combined malonic and methylmalonic aciduria (PMID: 21841779). Although the p.Arg471Trp change in the homozygous state has not been reported to cause a significant clinical phenotype to date, it has not been reported in compound heterozygous state with a potentially more damaging mutation and therefore the full spectrum of disease associated with the p.Arg471Gln change is not currently known. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 02, 2022 | Published functional studies of the equivalent residue in E. coli resulted in complete loss of fatty acyl-CoA synthetase enzymatic activity (Black et al., 1997); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 29858964, 21841779, 9030548, 21785126) - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 04, 2024 | The c.1411C>T (p.R471W) alteration is located in exon 9 (coding exon 7) of the ACSF3 gene. This alteration results from a C to T substitution at nucleotide position 1411, causing the arginine (R) at amino acid position 471 to be replaced by a tryptophan (W). Based on data from gnomAD, the T allele has an overall frequency of 0.029% (82/282622) total alleles studied. The highest observed frequency was 0.705% (73/10360) of Ashkenazi Jewish alleles. This variant has been identified in the homozygous state in individuals with elevated plasma MMA, plasma MA, and/or elevated urine MMA, urine MA, with lack of expected metabolic disease symptoms (Alfares, 2011; Sloan, 2011). Another alteration at the same codon, c.1412G>A (p.R471Q), has been detected in in one individual with hypoglycemia, acidosis, poor weight gain, diarrhea episodes, and biochemical findings consistent with combined malonic and methylmalonic aciduria (Sloan, 2011). This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. - |
Methylmalonic acidemia Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
D;D;D;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
.;D;.;D;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;H;H;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;.;D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;.;D;D;D
Sift4G
Pathogenic
D;D;D;D;D
Polyphen
D;D;D;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at